Modulating polybasic character of galactose-based glycosylated antitumor ether lipids for enhanced cytotoxic response

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• Ether lipids are a class of compounds with potential anticancer properties.
• Glycosylation can modulate the biological activity and pharmacokinetic properties of drug candidates.
• Previous studies have shown the potential of galactose-based glycosylated antitumor ether lipids (GAELs).

Purpose of the Study:

• To investigate the structure-activity relationship (SAR) of GAELs by modifying amine group positions.
• To synthesize and evaluate novel dibasic and tribasic galacto-GAEL analogues.
• To identify GAELs with enhanced antitumor activity against human epithelial cancer cell lines.

Main Methods:

• Synthesis of various galactose-based GAEL analogues with amine groups at different positions on the galactose and glycerol moieties.
• In vitro evaluation of synthesized compounds against a panel of human epithelial cancer cell lines.
• Determination of CC50 values and assessment of the mechanism of cell death, including caspase activation.

Main Results:

• A specific β-anomeric triamino galactose scaffold demonstrated the highest potency.
• This lead compound exhibited CC50 values ranging from 2.6 ± 0.2 μM to 6.5 ± 0.1 μM against tested cancer cell lines.
• The most active GAEL displayed superior efficacy compared to cisplatin in killing cancer cells.
• The compound's cell-killing mechanism did not involve caspase activation, suggesting a non-apoptotic pathway.

Conclusions:

• The position and number of amine groups significantly influence the antitumor activity of GAELs.
• The identified β-anomeric triamino galactose GAEL is a promising lead compound for epithelial cancer therapy.
• The non-apoptotic cell death mechanism warrants further investigation for novel therapeutic strategies.